A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances

被引:0
|
作者
Cao, Yiyin [1 ]
Li, Haofei [1 ]
Cheng, Ling Jie [2 ]
King, Madeleine T. [3 ]
Kemmler, Georg [4 ]
Cella, David [5 ]
Yu, Hongjuan [6 ]
Huang, Weidong [1 ]
Luo, Nan [2 ]
机构
[1] Harbin Med Univ, Sch Hlth Management, Harbin 150081, Peoples R China
[2] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore
[3] Univ Sydney, Sch Psychol, Sydney 2006, Australia
[4] Innsbruck Med Univ, Dept Psychiat & Psychotherapy, Innsbruck, Austria
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60601 USA
[6] Harbin Med Univ, Dept Hematol, Affiliated Hosp 1, Harbin, Peoples R China
来源
HEALTH ECONOMICS REVIEW | 2024年 / 14卷 / 01期
基金
中国国家自然科学基金;
关键词
QLU-C10D; FACT-8D; Measurement properties; Cancer; Hematological malignance; QUALITY-OF-LIFE; CANCER CLINICAL-TRIALS; FUNCTIONAL ASSESSMENT; REPORTED OUTCOMES; HEALTH-STATUS; EUROPEAN-ORGANIZATION; INSTRUMENT; RESPONSIVENESS; QUESTIONNAIRE; QLQ-C30;
D O I
10.1186/s13561-024-00560-0
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective To perform a comparison of the measurement properties of two cancer-specific Multi-Attribute Utility Instruments (MAUIs), EORTC QLU-C10D and FACT-8D, in Chinese patients with hematologic malignancies (HM). Methods We conducted a longitudinal study on patients with HM in China, using QLU-C10D and FACT-8D at baseline and follow-up (3-4 months from baseline). We assessed: (i) convergent validity using Spearman's rank correlation test (r) with EQ-5D-5L; (ii) clinical-groups validity by differentiating cancer stages, overall health assessment (OHA), Eastern Cancer Oncology Group (ECOG) performance status, and mental health status. We also examined clinical validity with effect size (ES) and relative efficiency (RE); (iii) responsiveness to changes in patient self-perception using receiver operating characteristics (ROC) curves and area under the curves (AUC); and (iv) agreement using intraclass correlation coefficients (ICC) and visualized with Bland-Altman plot. Results Among the 308 patients with HM at baseline, 131 completed the follow-up survey. Agreement between the two measures was high (ICC = 0.76). Both measures were highly correlated with EQ-5D-5 L and significantly differentiated (p < 0.001) among groups categorized by cancer stage, OHA performance status, and mental health. ESs for QLU-C10D were numerically higher for cancer stage, OHA, and performance status (ES = 0.53-1.49), whereas ES was higher for FACT-8D and mental health status (ES = 1.35). Responsiveness was higher for QLU-C10D (AUC = 0.84) compared to FACT-8D (AUC = 0.78). Conclusion Both QLU-C10D and FACT-8D are valid cancer-specific MAUIs for evaluating patients with HM. However, scholars should consider their slight differences in focus when choosing between the two measures.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
    Femke Jansen
    Irma M. Verdonck-de Leeuw
    Eva Gamper
    Richard Norman
    Bernhard Holzner
    Madeleine King
    Georg Kemmler
    Quality of Life Research, 2021, 30 : 2009 - 2019
  • [22] Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score
    Klapproth, Christoph Paul
    Fischer, Felix
    Rose, Matthias
    Karsten, Maria Margarete
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 152 : 101 - 109
  • [23] Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
    Jansen, Femke
    Verdonck-de Leeuw, Irma M.
    Gamper, Eva
    Norman, Richard
    Holzner, Bernhard
    King, Madeleine
    Kemmler, Georg
    QUALITY OF LIFE RESEARCH, 2021, 30 (07) : 2009 - 2019
  • [24] Cancer-specific health utilities: Evaluation of the clinical validity and measurement properties of the EORTC QLU-C10D in various cancer populations
    Pilz, Micha Johannes
    Seyringer, Simone
    King, Madeleine
    Bottomley, Andrew
    Norman, Richard
    Schlosser, Lisa
    Hell, Tobias
    Gamper, Eva Maria
    MEDICAL DECISION MAKING, 2024, 44 (02) : NP157 - NP158
  • [25] EORTC QLU-C10D valuation studies in various European countries-findings and outlook
    Kemmler, Georg
    Gamper, Eva
    Holzner, Bernhard
    Norman, Richard
    King, Madeleine
    QUALITY OF LIFE RESEARCH, 2019, 28 : S11 - S11
  • [26] Comparison of the PROMIS Preference Score (PROPr), EQ-5D-5L and EORTC QLU-C10D in cancer patients receiving chemotherapy
    Doehmen, Annika
    Obbarius, Alexander
    Kock, Milan
    Rohde, Jens
    Fischer, Felix
    Keilholz, Ulrich
    Rose, Matthias
    Klapproth, Christoph Paul
    QUALITY OF LIFE RESEARCH, 2022, 31 : S63 - S63
  • [27] Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D
    Cao, Yiyin
    Xu, Juan
    Norman, Richard
    King, Madeleine T.
    Kemmler, Georg
    Huang, Weidong
    Luo, Nan
    QUALITY OF LIFE RESEARCH, 2024, 33 (12) : 3335 - 3349
  • [28] The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights
    Eva-Maria Gamper
    Madeleine T. King
    Richard Norman
    Fanny L. C. Loth
    Bernhard Holzner
    Georg Kemmler
    Journal of Patient-Reported Outcomes, 6
  • [29] The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights
    Gamper, Eva-Maria
    King, Madeleine T.
    Norman, Richard
    Loth, Fanny L. C.
    Holzner, Bernhard
    Kemmler, Georg
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2022, 6 (01)
  • [30] Measuring Utilities in Cancer Patients - The EORTC QLU C10D
    Buettner, Matthias
    Gamperl, Eva
    Kemmler, Georg
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 102 - 102